• Something wrong with this record ?

Prolonged FGF21 treatment increases energy expenditure and induces weight loss in obese mice independently of UCP1 and adrenergic signaling

S. Stanic, K. Bardova, P. Janovska, M. Rossmeisl, J. Kopecky, P. Zouhar

. 2024 ; 221 (-) : 116042. [pub] 20240206

Language English Country England, Great Britain

Document type Journal Article

Fibroblast growth factor 21 (FGF21) reduces body weight, which was attributed to induced energy expenditure (EE). Conflicting data have been published on the role of uncoupling protein 1 (UCP1) in this effect. Therefore, we aimed to revisit the thermoregulatory effects of FGF21 and their implications for body weight regulation. We found that an 8-day treatment with FGF21 lowers body weight to similar extent in both wildtype (WT) and UCP1-deficient (KO) mice fed high-fat diet. In WT mice, this effect is solely due to increased EE, associated with a strong activation of UCP1 and with excess heat dissipated through the tail. This thermogenesis takes place in the interscapular region and can be attenuated by a β-adrenergic inhibitor propranolol. In KO mice, FGF21-induced weight loss correlates with a modest increase in EE, which is independent of adrenergic signaling, and with a reduced energy intake. Interestingly, the gene expression profile of interscapular brown adipose tissue (but not subcutaneous white adipose tissue) of KO mice is massively affected by FGF21, as shown by increased expression of genes encoding triacylglycerol/free fatty acid cycle enzymes. Thus, FGF21 elicits central thermogenic and pyretic effects followed by a concomitant increase in EE and body temperature, respectively. The associated weight loss is strongly dependent on UCP1-based thermogenesis. However, in the absence of UCP1, alternative mechanisms of energy dissipation may contribute, possibly based on futile triacylglycerol/free fatty acid cycling in brown adipose tissue and reduced food intake.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24006878
003      
CZ-PrNML
005      
20240423155542.0
007      
ta
008      
240412e20240206enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.bcp.2024.116042 $2 doi
035    __
$a (PubMed)38325495
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Stanic, Sara $u Laboratory of Adipose Tissue Biology, Institute of Physiology of the Czech Academy of Sciences, Videnska 1083, Prague 142 00, Czech Republic; Faculty of Science, Charles University in Prague, Vinicna 7, Prague 128 44, Czech Republic
245    10
$a Prolonged FGF21 treatment increases energy expenditure and induces weight loss in obese mice independently of UCP1 and adrenergic signaling / $c S. Stanic, K. Bardova, P. Janovska, M. Rossmeisl, J. Kopecky, P. Zouhar
520    9_
$a Fibroblast growth factor 21 (FGF21) reduces body weight, which was attributed to induced energy expenditure (EE). Conflicting data have been published on the role of uncoupling protein 1 (UCP1) in this effect. Therefore, we aimed to revisit the thermoregulatory effects of FGF21 and their implications for body weight regulation. We found that an 8-day treatment with FGF21 lowers body weight to similar extent in both wildtype (WT) and UCP1-deficient (KO) mice fed high-fat diet. In WT mice, this effect is solely due to increased EE, associated with a strong activation of UCP1 and with excess heat dissipated through the tail. This thermogenesis takes place in the interscapular region and can be attenuated by a β-adrenergic inhibitor propranolol. In KO mice, FGF21-induced weight loss correlates with a modest increase in EE, which is independent of adrenergic signaling, and with a reduced energy intake. Interestingly, the gene expression profile of interscapular brown adipose tissue (but not subcutaneous white adipose tissue) of KO mice is massively affected by FGF21, as shown by increased expression of genes encoding triacylglycerol/free fatty acid cycle enzymes. Thus, FGF21 elicits central thermogenic and pyretic effects followed by a concomitant increase in EE and body temperature, respectively. The associated weight loss is strongly dependent on UCP1-based thermogenesis. However, in the absence of UCP1, alternative mechanisms of energy dissipation may contribute, possibly based on futile triacylglycerol/free fatty acid cycling in brown adipose tissue and reduced food intake.
650    _2
$a zvířata $7 D000818
650    _2
$a myši $7 D051379
650    _2
$a myši obézní $7 D008820
650    _2
$a uncoupling protein 1 $x genetika $7 D000071256
650    12
$a kyseliny mastné neesterifikované $7 D005230
650    12
$a hmotnostní úbytek $7 D015431
650    _2
$a tělesná hmotnost $7 D001835
650    _2
$a energetický metabolismus $7 D004734
650    _2
$a adrenergní látky $7 D018663
650    _2
$a triglyceridy $7 D014280
650    12
$a fibroblastové růstové faktory $7 D005346
655    _2
$a časopisecké články $7 D016428
700    1_
$a Bardova, Kristina $u Laboratory of Adipose Tissue Biology, Institute of Physiology of the Czech Academy of Sciences, Videnska 1083, Prague 142 00, Czech Republic
700    1_
$a Janovska, Petra $u Laboratory of Adipose Tissue Biology, Institute of Physiology of the Czech Academy of Sciences, Videnska 1083, Prague 142 00, Czech Republic
700    1_
$a Rossmeisl, Martin $u Laboratory of Adipose Tissue Biology, Institute of Physiology of the Czech Academy of Sciences, Videnska 1083, Prague 142 00, Czech Republic
700    1_
$a Kopecky, Jan $u Laboratory of Adipose Tissue Biology, Institute of Physiology of the Czech Academy of Sciences, Videnska 1083, Prague 142 00, Czech Republic
700    1_
$a Zouhar, Petr $u Laboratory of Adipose Tissue Biology, Institute of Physiology of the Czech Academy of Sciences, Videnska 1083, Prague 142 00, Czech Republic. Electronic address: petr.zouhar@fgu.cas.cz
773    0_
$w MED00000704 $t Biochemical pharmacology $x 1873-2968 $g Roč. 221 (20240206), s. 116042
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38325495 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155539 $b ABA008
999    __
$a ok $b bmc $g 2081074 $s 1216645
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 221 $c - $d 116042 $e 20240206 $i 1873-2968 $m Biochemical pharmacology $n Biochem Pharmacol $x MED00000704
LZP    __
$a Pubmed-20240412

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...